AU2003269354B2 - Methods for promoting dopaminergic neuronal development by using NG4A-subfamily and Wnt-ligands - Google Patents

Methods for promoting dopaminergic neuronal development by using NG4A-subfamily and Wnt-ligands Download PDF

Info

Publication number
AU2003269354B2
AU2003269354B2 AU2003269354A AU2003269354A AU2003269354B2 AU 2003269354 B2 AU2003269354 B2 AU 2003269354B2 AU 2003269354 A AU2003269354 A AU 2003269354A AU 2003269354 A AU2003269354 A AU 2003269354A AU 2003269354 B2 AU2003269354 B2 AU 2003269354B2
Authority
AU
Australia
Prior art keywords
cell
wnt
stem
neural
progenitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003269354A
Other languages
English (en)
Other versions
AU2003269354A1 (en
Inventor
Ernesto Arenas
Goncalo Castelo Branco
Kyle Sousa
Joseph Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeuroTherapeutics AB
Original Assignee
NeuroTherapeutics AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0222162A external-priority patent/GB0222162D0/en
Application filed by NeuroTherapeutics AB filed Critical NeuroTherapeutics AB
Publication of AU2003269354A1 publication Critical patent/AU2003269354A1/en
Application granted granted Critical
Publication of AU2003269354B2 publication Critical patent/AU2003269354B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9413—Dopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1783—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Engineering & Computer Science (AREA)
AU2003269354A 2002-09-24 2003-09-24 Methods for promoting dopaminergic neuronal development by using NG4A-subfamily and Wnt-ligands Ceased AU2003269354B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US41304602P 2002-09-24 2002-09-24
GB0222162.0 2002-09-24
GB0222162A GB0222162D0 (en) 2002-09-24 2002-09-24 Methods and materials relating to neurogenesis
US60/413,046 2002-09-24
US49459503P 2003-08-12 2003-08-12
US60/494,595 2003-08-12
PCT/IB2003/004598 WO2004029229A2 (en) 2002-09-24 2003-09-24 Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands

Publications (2)

Publication Number Publication Date
AU2003269354A1 AU2003269354A1 (en) 2004-04-19
AU2003269354B2 true AU2003269354B2 (en) 2008-03-06

Family

ID=32045676

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003269354A Ceased AU2003269354B2 (en) 2002-09-24 2003-09-24 Methods for promoting dopaminergic neuronal development by using NG4A-subfamily and Wnt-ligands

Country Status (6)

Country Link
US (2) US20060233771A1 (https=)
EP (1) EP1597355A2 (https=)
JP (1) JP2006509497A (https=)
AU (1) AU2003269354B2 (https=)
CA (1) CA2523618A1 (https=)
WO (1) WO2004029229A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1779867A4 (en) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd MEANS FOR PROMOTING NERVE REVENERATION
EP1791949A2 (en) * 2004-09-02 2007-06-06 Neuro Therapeutics AB Methods and materials relating to enhanced production of dopamine neurons
EP1827470A2 (en) * 2004-12-09 2007-09-05 Neuro Therapeutics AB Materials and methods related to dickkopfs (dkk) and neurogenesis
WO2006091766A2 (en) 2005-02-24 2006-08-31 Jau-Nan Lee Human trophoblast stem cells and use thereof
EP1871407A2 (en) * 2005-03-31 2008-01-02 The University Of Chicago Compositions comprising wnt-3 peptide for modulating medial-lateral neuronal topographic maps
WO2007119180A2 (en) * 2006-04-07 2007-10-25 Neuro Therapeutics Ab Survival and development of neural cells
WO2009011892A2 (en) * 2007-07-18 2009-01-22 Boston Biomedical Research Institute Use of suif proteins and heparan sulfate in gdnf-dependent neural innervation and protection
FR2925903B1 (fr) * 2008-01-02 2011-01-21 Sanofi Aventis DERIVES 6-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
US20110244569A1 (en) * 2008-05-13 2011-10-06 Tara Louise Walker Method of inducing proliferation and/or differentiation of neural precursor cells by introducing prolactin or wnt3a to activate latent neural precursor cells
EP2352817B1 (en) * 2008-10-31 2016-01-27 University Of Louisville Research Foundation, Inc. Olfactory epithelial-derived stem cells and methods of use therefor
JP5802195B2 (ja) * 2009-04-27 2015-10-28 オタワ ホスピタル リサーチ インスティチュート 幹細胞を調節するための組成物および方法ならびにその使用
WO2012068170A2 (en) 2010-11-15 2012-05-24 Jau-Nan Lee Generation of neural stem cells from human trophoblast stem cells
TWI481715B (zh) * 2010-11-15 2015-04-21 Jau Nan Lee 從人類滋養層幹細胞中生成神經幹細胞
WO2013040341A2 (en) 2011-09-16 2013-03-21 Ottawa Hospital Research Institute Wnt7a compositions and methods of using the same
JP2014527818A (ja) 2011-09-16 2014-10-23 フェイト セラピューティクス，インコーポレイテッド Ｗｎｔ組成物およびそのような組成物の治療的使用
WO2014085493A1 (en) 2012-11-30 2014-06-05 Jau-Nan Lee Methods of differentiating stem cells by modulating mir-124
US9808490B2 (en) 2014-11-26 2017-11-07 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
KR101695429B1 (ko) * 2015-10-15 2017-01-12 한국과학기술연구원 생체외에서 운동 신경세포의 배양 촉진을 위한 코엔자임 q10을 포함하는 조성물
JP2019106895A (ja) * 2017-12-15 2019-07-04 インダストリー‐ユニバーシティー コーぺレーション ファンデーション ハンヤン ユニバーシティ 神経幹細胞または神経前駆細胞からドーパミン神経細胞への分化方法
TWI772790B (zh) 2019-05-06 2022-08-01 美商加速生物科學有限公司 前驅調節滋胚內層細胞及其用途
CN114836386A (zh) * 2022-04-20 2022-08-02 电子科技大学 一种负载Wnt1蛋白且靶向脑组织的工程化外泌体及其制备方法和应用
WO2025193168A1 (en) * 2024-03-14 2025-09-18 National University Of Singapore Method of generating midbrain dopamine progenitors and neurons from stem cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06157554A (ja) * 1992-11-27 1994-06-03 Toray Dow Corning Silicone Co Ltd トリオルガノクロロシランの製造方法
US6277820B1 (en) * 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
US6610540B1 (en) * 1998-11-18 2003-08-26 California Institute Of Technology Low oxygen culturing of central nervous system progenitor cells
US6312949B1 (en) * 1999-03-26 2001-11-06 The Salk Institute For Biological Studies Regulation of tyrosine hydroxylase expression
DE60035191T2 (de) * 1999-05-03 2008-06-19 Neuro Therapeutics Ab Materialien und methoden zur entwicklung von dopaminergen neuronen
WO2001088100A1 (en) * 2000-05-16 2001-11-22 Kyowa Hakko Kogyo Co., Ltd. Novel method of inducing the differentiation of embryonic stem cells into ectodermal cells and use thereof
WO2001088104A2 (en) * 2000-05-17 2001-11-22 Geron Corporation Neural progenitor cell populations
US20020114788A1 (en) * 2000-07-27 2002-08-22 Ole Isacson Cell implantation therapy for neurological diseases or disorders
US20030211605A1 (en) * 2001-05-01 2003-11-13 Lee Sang-Hun Derivation of midbrain dopaminergic neurons from embryonic stem cells

Also Published As

Publication number Publication date
US20090087417A1 (en) 2009-04-02
JP2006509497A (ja) 2006-03-23
EP1597355A2 (en) 2005-11-23
US20060233771A1 (en) 2006-10-19
AU2003269354A1 (en) 2004-04-19
CA2523618A1 (en) 2004-04-08
WO2004029229A2 (en) 2004-04-08
WO2004029229A3 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
US20090087417A1 (en) Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands
US6284539B1 (en) Method for generating dopaminergic cells derived from neural precursors
Gascon et al. PSA-NCAM in postnatally generated immature neurons of the olfactory bulb: a crucial role in regulating p75 expression and cell survival
EP1173548B1 (en) Materials and methods for the production of dopaminergic neurons
Schwartz et al. Stromal factors SDF1α, sFRP1, and VEGFD induce dopaminergic neuron differentiation of human pluripotent stem cells
CN110684734A (zh) 用于植入的中脑多巴胺（da）神经元
Chen et al. Insulin-like growth factor 1 partially rescues early developmental defects caused by SHANK2 knockdown in human neurons
Wei et al. Effects of engrafted neural stem cells derived from GFP transgenic mice in Parkinson's diseases rats
Corvaglia et al. ProNGF is a cell-type-specific mitogen for adult hippocampal and for induced neural stem cells
WO2008071960A2 (en) Methods of increasing neurogenesis
US20090226536A1 (en) Methods and materials relating to enhanced production of dopamine neurons
WO2006061717A2 (en) Materials and methods related to dickkopfs (dkk) and neurogenesis
AU2004202661B2 (en) Materials and methods relating to neuronal development
Zheng et al. Neuregulin regulates the formation of radial glial scaffold in hippocampal dentate gyrus of postnatal rats
WO2007119180A2 (en) Survival and development of neural cells
Tonnesen Gene Therapy for Neurological Disorders Stem Cell and Optogenetic Strategies
Wyatt The Physiological Relevance of hMNP Transplantation into the SMNdelta7 Murine Model of Spinal Muscular Atrophy
TING Molecular and morphological characterization of caudal neural tube defects in embryos of diabetic swiss albino mice
Hoang-Minh Circadian control of adult neural progenitor cell behavior in vivo and in vitro: A molecular and genetic screen of regulatory candidates for neuroregenerative therapies
Chabrat Role of Lmx1a and Lmx1b Transcription Factors in Post-Mitotic Midbrain Dopaminergic Neurons Thèse Audrey Chabrat Doctorat en neurobiologie
Lanciego et al. Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 24 MAY 2005.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired